Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Freeline management to meet virtually with BTIG » 12:50
12/02/21
12/02
12:50
12/02/21
12:50
FRLN

Freeline

$2.29 /

+0.04 (+1.78%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRLN Freeline
$2.29 /

+0.04 (+1.78%)

FRLN Freeline
$2.29 /

+0.04 (+1.78%)

11/29/21 BTIG
Freeline initiated with a Buy at BTIG
11/29/21 BTIG
Freeline initiated with a Buy at BTIG
10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
FRLN Freeline
$2.29 /

+0.04 (+1.78%)

Tuesday
Conference/Events
Freeline participates on a conference call with JPMorgan » 12:25
11/30/21
11/30
12:25
11/30/21
12:25
FRLN

Freeline

$2.31 /

-0.075 (-3.14%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Joseph holds a conference call with CEO Parini on November 30 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
FRLN Freeline
$2.31 /

-0.075 (-3.14%)

FRLN Freeline
$2.31 /

-0.075 (-3.14%)

11/29/21 BTIG
Freeline initiated with a Buy at BTIG
11/29/21 BTIG
Freeline initiated with a Buy at BTIG
10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
FRLN Freeline
$2.31 /

-0.075 (-3.14%)

Conference/Events
Freeline participates on a conference call with JPMorgan » 09:48
11/30/21
11/30
09:48
11/30/21
09:48
FRLN

Freeline

$2.37 /

-0.015 (-0.63%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Joseph holds a conference call with CEO Parini on November 30 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
FRLN Freeline
$2.37 /

-0.015 (-0.63%)

FRLN Freeline
$2.37 /

-0.015 (-0.63%)

11/29/21 BTIG
Freeline initiated with a Buy at BTIG
11/29/21 BTIG
Freeline initiated with a Buy at BTIG
10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
FRLN Freeline
$2.37 /

-0.015 (-0.63%)

Monday
Initiation
Freeline initiated with a Buy at BTIG » 06:35
11/29/21
11/29
06:35
11/29/21
06:35
FRLN

Freeline

/

+

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Freeline with a Buy rating and $10 price target. The stock trades at negative enterprise value despite having the most recognized pioneer in hemophilia gene therapy as its founder and having built a next-generation gene therapy platform due to competition for both the hemophilia B and Fabry programs, the analyst tells investors in a research note. Given the initial data in Phase 1/2 study in Fabry disease and the company's Phase 3 study planned for mid-2023, Zhong adds that Freeline's identification of the optimal dose should still allow each program to be competitive, and he sees favorable risk-reward ratio at the current share price.

ShowHide Related Items >><<
FRLN Freeline
/

+

FRLN Freeline
/

+

11/29/21 BTIG
Freeline initiated with a Buy at BTIG
10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
FRLN Freeline
/

+

Initiation
Freeline initiated with a Buy at BTIG » 06:28
11/29/21
11/29
06:28
11/29/21
06:28
FRLN

Freeline

$2.33 /

-0.05 (-2.10%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Freeline with a Buy rating and $10 price target.

ShowHide Related Items >><<
FRLN Freeline
$2.33 /

-0.05 (-2.10%)

FRLN Freeline
$2.33 /

-0.05 (-2.10%)

10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
FRLN Freeline
$2.33 /

-0.05 (-2.10%)

Over a week ago
Hot Stocks
Kaleido Biosciences to appoint Alison Long as Chief Medical Officer » 07:47
11/10/21
11/10
07:47
11/10/21
07:47
KLDO

Kaleido Biosciences

$4.40 /

-0.09 (-2.00%)

, FRLN

Freeline

$3.13 /

-0.115 (-3.54%)

Kaleido Biosciences…

Kaleido Biosciences (KLDO) announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido's ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively. Dr. Long most recently served as interim Chief Medical Officer and Senior Vice President, Head of Clinical Development at Freeline Therapeutics (FRLN), and was responsible for the clinical development, clinical operations, medical affairs, and regulatory functions of Freeline's development programs.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$4.40 /

-0.09 (-2.00%)

FRLN Freeline
$3.13 /

-0.115 (-3.54%)

KLDO Kaleido Biosciences
$4.40 /

-0.09 (-2.00%)

10/19/21 Morgan Stanley
Kaleido Biosciences assumed at Underweight from Equal Weight at Morgan Stanley
07/22/21 JMP Securities
Seres trial news 'disappointing,' but an isolated story, says JMP
07/09/21 Chardan
Kaleido Biosciences assumed with a Buy at Chardan
02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
FRLN Freeline
$3.13 /

-0.115 (-3.54%)

10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
KLDO Kaleido Biosciences
$4.40 /

-0.09 (-2.00%)

FRLN Freeline
$3.13 /

-0.115 (-3.54%)

  • 04
    Feb
Hot Stocks
Freeline updates data from Fabry disease program, Pamela Foulds MD, named CMO » 16:20
11/09/21
11/09
16:20
11/09/21
16:20
FRLN

Freeline

$3.13 /

-0.115 (-3.54%)

Freeline Therapeutics…

Freeline Therapeutics Holdings announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer, CMO, and reported financial results for the third quarter of 2021. "Today we are pleased to announce that enzyme expression data from the second patient in our Phase 1/2 dose-finding trial of FLT190 are highly encouraging, with expression of alpha-galactosidase A reaching near-normal levels and the patient thus far remaining off enzyme replacement therapy since dosing," said Michael Parini, Chief Executive Officer of Freeline. "These results were achieved in our lowest dose cohort and already FLT190 appears to be having a significant impact on alpha-Gal A activity and disease process in Fabry, which is the underlying goal and promise of the FLT190 program. We also learned that our proactive immune management regimen, which is being deployed across all of our programs, has been effective as no elevations of liver enzymes have been observed throughout the treatment period." "We are also delighted to further build our leadership team with the addition of Dr. Pamela Foulds, whom we welcome to Freeline as our new Chief Medical Officer," said Mr. Parini. "Given our continued focus on delivering our clinical-stage assets and identifying new disease opportunities to tackle with our potent capsid and strong protein engineering capabilities, Pam's expertise will be invaluable as we evaluate our programs and determine how to best advance them and unlock the value in our pipeline." "We will be dosing a third patient in the first dose cohort of MARVEL-1, which will allow us to gather additional information on a potential risk of mild and transient myocarditis in this patient population with underlying and contributory cardiac disease. This step is consistent with the recommendation of our independent Data Monitoring Committee, with whom we have worked to review the data."

ShowHide Related Items >><<
FRLN Freeline
$3.13 /

-0.115 (-3.54%)

FRLN Freeline
$3.13 /

-0.115 (-3.54%)

10/19/21 Morgan Stanley
Freeline assumed with an Overweight at Morgan Stanley
08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
FRLN Freeline
$3.13 /

-0.115 (-3.54%)

Over a month ago
Initiation
Freeline assumed with an Overweight at Morgan Stanley » 08:33
10/19/21
10/19
08:33
10/19/21
08:33
FRLN

Freeline

$3.10 /

-0.17 (-5.21%)

Morgan Stanley analyst…

Morgan Stanley analyst Michael Ulz assumed coverage of Freeline with an Overweight rating with a price target of $9, down from $22. Freeline has a differentiated gene therapy platform for potentially curative treatments for chronic systemic diseases and the recent management transition, combined with continued pipeline progress, "set the stage for potential upside," Ulz tells investors.

ShowHide Related Items >><<
FRLN Freeline
$3.10 /

-0.17 (-5.21%)

FRLN Freeline
$3.10 /

-0.17 (-5.21%)

08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
08/16/21 Mizuho
Freeline downgraded to Neutral from Buy at Mizuho
FRLN Freeline
$3.10 /

-0.17 (-5.21%)

Hot Stocks
ProQR Therapeutics appoints Theresa Heggie as CCO » 08:14
10/04/21
10/04
08:14
10/04/21
08:14
PRQR

ProQR Therapeutics

$8.23 /

-0.11 (-1.32%)

, FRLN

Freeline

$3.41 /

-0.06 (-1.73%)

ProQR Therapeutics…

ProQR Therapeutics announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for overseeing the Company's commercial strategy and global commercial operations. She joins as the Company prepares for the top-line results from its Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 in the first half of 2022. Ms. Heggie most recently served as Chief Executive Officer of Freeline Therapeutics. In connection with her appointment as Chief Commercial Officer, Ms. Heggie has stepped down from the Supervisory Board of ProQR.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
$8.23 /

-0.11 (-1.32%)

FRLN Freeline
$3.41 /

-0.06 (-1.73%)

PRQR ProQR Therapeutics
$8.23 /

-0.11 (-1.32%)

09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
05/03/21 Stifel
ProQR Therapeutics initiated with a Buy at Stifel
03/25/21 Citi
ProQR Therapeutics price target raised to $44 from $33 at Citi
03/24/21 Cantor Fitzgerald
ProQR Therapeutics price target raised to $33 from $22 at Cantor Fitzgerald
FRLN Freeline
$3.41 /

-0.06 (-1.73%)

08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
08/16/21 Mizuho
Freeline downgraded to Neutral from Buy at Mizuho
PRQR ProQR Therapeutics
$8.23 /

-0.11 (-1.32%)

FRLN Freeline
$3.41 /

-0.06 (-1.73%)

  • 31
    Mar
PRQR ProQR Therapeutics
$8.23 /

-0.11 (-1.32%)

Syndicate
Freeline files $250M mixed securities shelf  16:03
09/10/21
09/10
16:03
09/10/21
16:03
FRLN

Freeline

$3.84 /

-0.16 (-4.00%)

 
ShowHide Related Items >><<
FRLN Freeline
$3.84 /

-0.16 (-4.00%)

FRLN Freeline
$3.84 /

-0.16 (-4.00%)

08/18/21 H.C. Wainwright
Freeline price target lowered to $20 from $30 at H.C. Wainwright
08/17/21 JPMorgan
Freeline downgraded on lack of value creation opportunities at JPMorgan
08/17/21 JPMorgan
Freeline downgraded to Neutral from Overweight at JPMorgan
08/16/21 Mizuho
Freeline downgraded to Neutral from Buy at Mizuho
FRLN Freeline
$3.84 /

-0.16 (-4.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.